ESR1 and breast carcinoma: Because tamoxifen-resistant breast cancers rarely harbor ESR1 mutations, which confer only partial resistance to tamoxifen [47–50], the upstream molecular regulator of H19 in developing tamoxifen resistance remains to be investigated.